Oregon Therapeutics & Lantern Pharma Collaborate To Optimize Cancer Drug

By Author: Orson Amiri
Total Articles: 397
Comment this article

Lantern Pharma Inc. (NASDAQ: LTRN) and Oregon Therapeutics, a French biotech company, have joined forces in a strategic AI-driven collaboration to optimize the development of XCE853, a groundbreaking protein disulfide isomerase (PDI) inhibitor. XCE853 holds promise for various cancer indications, including drug-resistant ovarian and pancreatic cancer, hematological cancers, and pediatric cancers. Leveraging Lantern's RADR® AI platform, the collaboration aims to uncover biomarkers and efficacy-associated signatures of XCE853 across solid tumors, facilitating precision development and patient selection.

PDIs have emerged as promising targets for cancer therapy, particularly in cancers of poor prognosis like breast and ovarian cancer. Up-regulated expression of PDIs correlates with worse clinical outcomes in various cancers. Targeting PDIs disrupts cancer cell metabolism and induces proteotoxicity, offering a unique therapeutic strategy, especially against therapy-resistant cancers. With over 60 billion data points and 200 machine learning algorithms, RADR® will power the integration and interrogation of molecular data to identify biomarkers, resistance mechanisms, and additional therapeutic indications for XCE853. Under the collaboration, Lantern Pharma gains equal IP co-ownership and development rights, while Oregon Therapeutics benefits from financial rewards from IP out-licensing, marking a significant step in advancing personalized cancer treatment strategies.

Read More - https://www.techdogs.com/tech-news/business-wire/oregon-therapeutics-lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853-a-potent-inhibitor-of-cancer-metabolism